Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SAR408701 |
| Synonyms | |
| Therapy Description |
SAR408701 is an anti-CEACAM5 antibody in conjugation with DM4, which may lead to specific toxicity towards CEACAM5-expressing tumor cells (Eu J Cancer Dec 2016, 69(Suppl 1):S14-S15). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SAR408701 | SAR-408701|Tusamitamab ravtansine | CEACAM5 Antibody 12 | SAR408701 is an anti-CEACAM5 antibody in conjugation with DM4, which may lead to specific toxicity towards CEACAM5-expressing tumor cells (Eu J Cancer Dec 2016, 69(Suppl 1):S14-S15). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05245071 | Phase II | SAR408701 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06) | Terminated | USA | TUR | ITA | FRA | ESP | BEL | 1 |
| NCT04154956 | Phase III | SAR408701 Docetaxel | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUS | ARG | 8 |
| NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
| NCT05703555 | Phase II | SAR408701 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION) | Withdrawn | NLD | 0 |
| NCT04659603 | Phase II | SAR408701 Gemcitabine + SAR408701 | Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) | Terminated | USA | TUR | NLD | HUN | ESP | ARG | 4 |
| NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Terminated | USA | TUR | FRA | ESP | BEL | 0 |
CKB BOOST